Atara Biotherapeutics, Inc. (ATRA) vs ImmuCell Corporation (ICCC)
A side-by-side comparison of Atara Biotherapeutics, Inc. and ImmuCell Corporation across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
ATRA
Atara Biotherapeutics, Inc.
$9.40HealthcareDelayed quote: Oct 5, 2026, 4:00 PM EDT
ICCC
ImmuCell Corporation
$9.75HealthcareDelayed quote: Oct 5, 2026, 4:00 PM EDT
Total return — ATRA vs ICCC
growth of $100 · dividends reinvested · last 10yATRA -98.0% (-32.3%/yr)ICCC +26.0% (+2.3%/yr)ICCC compounded faster over this window
Log scale — wide-divergence pair
ATRA ICCC
ATRA vs ICCC: by the numbers
- •ICCC is the larger company ($88M vs $85M market cap).
- •ICCC is profitable (2.57% net margin) while ATRA runs a net loss (-269.42%).
- •ATRA grew revenue faster over the past five years (56.10% vs 13.74% CAGR).
Metrics side by side
Valuation
| Metric | ATRA | ICCC |
|---|---|---|
| P/E ratio | N/A | 115.25 |
| P/S ratio | 13.67 | 2.88 |
| P/B ratio | N/A | 2.81 |
| EV / EBITDA | N/A | 14.69 |
| FCF yield | N/A | 4.78% |
Profitability
| Metric | ATRA | ICCC |
|---|---|---|
| Gross margin | 82.44% | 40.32% |
| Operating margin | 29.69% | 12.60% |
| Net margin | -269.42% | 2.57% |
| ROE | N/A | 2.51% |
| ROIC | -100.35% | 8.16% |
Growth (annualized)
| Metric | ATRA | ICCC |
|---|---|---|
| Revenue CAGR (5Y) | 56.10% | 13.74% |
| Total return CAGR (5Y) | -53.60% | 0.65% |
Frequently asked
- Which has grown faster, ATRA or ICCC?
- Over the past five years, ATRA grew revenue faster — ATRA at a 56.10% CAGR versus ICCC at 13.74%.
- Is ATRA or ICCC more profitable?
- ICCC runs the higher net margin — ATRA at -269.42% versus ICCC at 2.57%.
- How have ATRA and ICCC total returns compared?
- Over the past 10 years, ATRA delivered -32.27% and ICCC delivered 2.46% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
ImmuCell P/E ratioAtara Biotherapeutics ROEImmuCell ROEAtara Biotherapeutics operating marginImmuCell operating marginAtara Biotherapeutics revenue growthImmuCell revenue growthAtara Biotherapeutics free cash flowImmuCell free cash flow
Atara Biotherapeutics & ImmuCell appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.